source
- Recon: BMS plans $2.3B Houston manufacturing site; MHRA approves Lilly weight-loss drug for weight loss, type 2 diabetesWelcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.raps · 1d ago↗ source
- Asia-Pacific Roundup: India establishes tougher penalties for filing misleading or fake documentsThe Indian government is preventing applicants who submit misleading, fake, or fabricated documents from filing further requests with regulatory authorities.raps · 1d ago↗ source
- FDA warns firm in India for falsified logbooks; two other companies warned for lax testingThe US Food and Drug Administration recently issued warning letters to an over-the-counter (OTC) drugmaker in India for submitting falsified logbooks to the agency. The agency also warned two other…